The workshop will provide an insight into the way OGT’s aCGH technology is making it possible for researchers worldwide to investigate the relationship between human disease and genome structure. Professor Stephen Rich, Director of the University of Virginia Center for Public Health Genomics, will be discussing the centre’s approach to “Designing a genome-wide structural variant search for type 1 diabetes loci”. Several areas of the human genome are known to be associated with an increased risk to type 1 diabetes, however most studies have concentrated on the influence of single nucleotide polymorphisms (SNPs). The new project will assess the importance of genome deletions, duplications and rearrangements for predisposing patients to diabetes. During his presentation, Professor Rich will address the concepts and challenges in designing a large-scale copy number variation (CNV) study, including experimental design, array design, sample selection and reducing potential sources of variation.
Professor Rich will be followed by Professor David Ledbetter of the Emory University School of Medicine, who will provide an update on recent developments regarding the International Standards for Cytogenomic Arrays (ISCA) Consortium and the ISCA Database. In addition, Professor Ledbetter will present data generated using OGT’s new CytoSure™ ISCA UPD array, which enables reliable detection of copy number changes and uniparental disomy on a single array using established aCGH methodology.
To register for the meeting (lunch provided), contact OGT at genomicservices@ogt.co.uk.
OGT will be exhibiting at the ASHG, and can be found at booth 1307. Find out more at www.ogt.co.uk.
For further information, please contact: Oxford Gene Technology, Begbroke Science Park, Sandy Lane, Yarnton, Oxford OX5 1PF T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684 ; E: products@ogt.co.uk W: www.ogt.co.uk
About Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) provides innovative clinical genetics and diagnostic solutions to advance molecular medicine. www.ogt.co.uk.
Clinical & Genomic Solutions: OGT’s Genefficiency™ is a unique combination of world-leading platforms, people, processing power and performance synchronised to deliver rapid, high quality genomic data to customers worldwide. The OGT CytoSure™ cytogenetics array, labelling and interpretation software products provide a complete solution for the detection of chromosomal abnormalities. Together, Genefficiency and CytoSure offer a unique, standardised and integrated solution for cytogenetics research.
Biomarker Discovery: OGT has a proven pedigree in genomic technology, which, together with the experience gained through the purchase of Sense Proteomics in 2009, enables OGT to develop highly specific customised genomic and proteomic biomarker panels for cancer and other diseases. OGT develops these for clinical screening and companion diagnostics requirements, both for direct sale and also for collaboration with partner companies.
CytoSure™: For research use only This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
